Clinical trials
High Risk clinical trials
Below are recruiting high risk clinical trials, each written for real people, not researchers. We’re tracking 941 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07181109RecruitingPhase 3
Study of zilebesiran for high-risk hypertension patients
This trial tests a new medicine called zilebesiran for people with high blood pressure that isn't well controlled. It may be an option if you have heart or blood vessel disease, or are at high risk for it.
Birmingham, AlabamaAges 18 years+ - NCT07001332Recruiting
High-risk heart stent procedure study
This study tests a new device to help people with high-risk blockages in their heart arteries during a stent procedure. It compares the new device to standard treatment to see if it is safe and effective.
Phoenix, ArizonaAges 18–88 - NCT05827549RecruitingPhase 2
Blinatumomab for relapsed ALL, matched by risk group
This Phase 2 study tests how well blinatumomab works for children and adults whose acute lymphoblastic leukemia (ALL) has come back. It also looks at whether results differ based on the patient’s relapse “risk group.”
DaeguAges 1–22 - NCT03896269RecruitingPhase 1
CPX-351 for high-risk MDS or CMML that came back
This Phase 1 trial studies CPX-351, a cancer medicine, in people with high-risk myelodysplastic syndrome (MDS) or chronic myelomonocytic leukemia (CMML) whose disease relapsed or did not respond to prior treatment. It may help shrink or control the leukemia and improve blood counts in patients who cannot or do not want a stem cell transplant.
Houston, TexasAges 18 years+ - NCT04047641RecruitingPhase 1/Phase 2
Quizartinib with chemotherapy for new or returning leukemia
This trial tests a combination of anti-leukemia drugs (including quizartinib) together with chemotherapy for people with acute myeloid leukemia (AML), a rare mixed-type leukemia, or high-risk myelodysplastic syndrome (MDS). It may help by trying to better control cancer in people whose disease is newly diagnosed or has returned/not responded to prior treatment.
Houston, TexasAges 18 years+ - NCT05013216RecruitingPhase 1
Vaccine trial for people at high risk of pancreatic cancer
This early-phase trial studies a long-peptide vaccine designed for people with certain genetic changes that raise the risk of pancreatic cancer. The goal is to help your immune system recognize and respond to cancer-related changes before cancer develops.
Baltimore, MarylandAges 40 years+ - NCT06640803Recruiting
Early psychosis risk stepped-care program
This study offers a step-by-step care program for teens and young adults at high risk for psychosis. It aims to provide the right level of support early on to prevent or reduce the severity of symptoms.
Elk Grove, CaliforniaAges 12–25 - NCT06461793RecruitingPhase 2
Higher dose radiation with hormone therapy for high-risk prostate cancer
This trial tests a higher dose of radiation given in fewer sessions (hypofractionated) combined with hormone therapy for men with high-risk prostate cancer that has not spread. A gel spacer called SpaceOAR is used to protect the rectum. The goal is to see if this approach is safe and effective.
SeoulAges 20 years+ - NCT07380217Recruiting
Using heart pump support for complex high-risk procedures
This trial is testing whether using a special heart pump (PulseCath iVAC2L) during complex, high-risk angioplasty can help people with very weak hearts. It's for people who need a procedure for complicated coronary artery blockages.
AmsterdamAges 18 years+ - NCT06394011RecruitingPhase 2
New drug combo for intermediate/high risk AML
This trial tests a new combination of drugs (VA plus HAAG) for adults newly diagnosed with intermediate or high-risk AML. It aims to see if this combination is safe and effective for people who haven't had prior treatment.
Suzhou, JiangsuAges 18–65 - NCT04783597Recruiting
Predict preeclampsia using blood vessel stiffness in pregnancy
This study looks for ways to predict preeclampsia (a pregnancy complication that can raise blood pressure and harm organs) early by measuring how stiff certain blood vessels are. If you’re considered higher risk, this could help identify problems sooner so your care team can watch you more closely.
Montreal, QuebecAges 18 years+ - NCT05345860Recruiting
Using MRD results to guide extra treatment after breast surgery
This trial checks “MRD” (tiny leftover cancer signals after surgery) to help decide the best additional treatment for early-stage breast cancer. It may help tailor therapy so you get the most useful medicines while avoiding unnecessary treatment.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06822439Recruiting
Remote fetal monitoring for high-risk pregnancies
This study tests if remote monitoring of your baby's heartbeat from home is a safe and effective option for high-risk pregnancies. It may reduce the need for frequent hospital visits.
Boston, MassachusettsAges 18 years+ - NCT07183878Recruiting
Venetoclax with BUCY conditioning for high-risk AML or MDS transplant
This trial tests whether adding venetoclax (a pill that targets cancer cells) to the standard chemotherapy regimen before a stem cell transplant improves outcomes for people with high-risk acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). It is for patients aged 12–60 whose cancer has specific high-risk features and who have a matched donor.
Hangzhou, ZhejiangAges 12–60 - NCT07774949Recruiting
Thyroid and anxiety effects on baby heart rate in high-risk pregnancy
This study looks at how thyroid function and anxiety in mothers might affect the baby's heart rate patterns (shown on a non-stress test) in high-risk pregnancies. The goal is to help doctors better understand and support high-risk pregnancies.
IstanbulAges 18–45 - NCT07774936Recruiting
Emotional factors and fetal monitoring in high-risk pregnancies
This study looks at how a pregnant person's feelings of control over their health and their anxiety levels relate to the results of a non-stress test (NST), which checks the baby's heartbeat and movements. It aims to improve care for high-risk pregnancies.
IstanbulAges 18–45 - NCT07538635RecruitingPhase 2
CAR-T cells plus stem cell transplant for aggressive lymphoma
This trial tests a two-step treatment for patients with an aggressive type of blood cancer (large B-cell lymphoma) that has come back or didn't respond well to standard therapy. You'll receive a stem cell transplant followed by CAR-T cells—specially engineered immune cells designed to fight cancer.
Hangzhou, ZhengjiangAges 18 years+ - NCT06204341Recruiting
Finding the best radiation for high-risk prostate cancer
This trial compares different radiation therapy plans for men with high-risk prostate cancer that has spread to the lymph nodes. It aims to find the best way to treat the prostate and the surrounding lymph nodes while minimizing side effects.
Leidschendam, South HollandAges 18 years+ - NCT07226895RecruitingPhase 1/Phase 2
Study of MT1988 for people at high risk for psychosis
This trial tests a new drug called MT1988 in people who show early warning signs of psychosis. Researchers want to see if it changes certain markers in the body related to mental health.
Irvine, CaliforniaAges 17–30 - NCT07720284RecruitingPhase 3
Testing new drugs for high-risk bladder cancer after surgery
This trial tests a new combination of drugs (Dato-DXd plus rilvegostomig) against standard treatments for people with high-risk, muscle-invasive bladder cancer that has been surgically removed. The goal is to see if the new treatment reduces the chance of the cancer coming back.
Hot Springs, ArkansasAges 18 years+ - NCT06327269RecruitingEarly Phase 1
Targeted therapy after liver transplant for high-risk liver cancer
This trial tests a targeted therapy (lenvatinib) given after a living-donor liver transplant to prevent high-risk liver cancer from coming back. It is for people whose cancer is aggressive or did not respond well to previous treatments.
Kaohsiung CityAges 18–75 - NCT06567743RecruitingPhase 2
Study of a new virus therapy for high-risk bladder cancer
This trial tests a new virus-based medicine, cretostimogene grenadenorepvec, given directly into the bladder for people with high-risk non-muscle-invasive bladder cancer. It may help prevent the cancer from coming back, especially for those who have not had BCG treatment or whose cancer did not respond to BCG.
Phoenix, ArizonaAges 18 years+ - NCT07025369RecruitingPhase 2
Hormone pill before PSMA scan for high-risk prostate cancer
This trial tests if giving a short-term hormone pill (relugolix) before a special PSMA PET/CT scan makes the scan clearer for men with high-risk prostate cancer. It may help doctors better see where the cancer is.
Scottsdale, ArizonaAges 18 years+ - NCT07180212Recruiting
Urine DNA Test to Guide Cystoscopy in High-Risk Bladder Cancer
This trial tests a urine test that looks for tumor DNA to help doctors decide when you need a cystoscopy (a scope in the bladder). It is for people with high-risk or very high-risk non-muscle-invasive bladder cancer who have already had surgery to remove all visible tumors.
Xingtai, HebeiAges 18 years+
Hear when a new High Risk trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for high risk?
- Yes. Clin2 currently lists 941 recruiting high risk studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a high risk trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a high risk trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.